橄聚烯 (Oleuropein Aglycone) 是一种橄聚,它会影响α-synuclein聚合,并在不同的帕金森病模型中产生神经保护作用
Milo J Basellini1,2, José M Granadino-Roldán3, Pablo V Torres-Ortega4
1Department of Biosciences, Università degli Studi di Milano, Milan, Italy.
Molecular neurobiology
|July 23, 2025
概括
橄的聚烯,oleuropein aglycone,显示神经保护作用对α-synuclein聚合,这是帕金森病的标志. 这种化合物改善了动物模型中的健康,寿命和运动功能.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔法-同核素聚合是神经退行性疾病的核心,如帕金森病.
- 治疗策略旨在减少α-synuclein聚合物或防止它们的形成.
- 自然化合物,特别是多,正在研究它们对抗α-synuclein病理的潜力.
研究的目的:
- 为了研究oleuropein aglycone对α-synuclein聚合和毒性的神经保护潜力.
- 在帕金森病的细胞和动物模型中评估oleuropein aglycone的疗效.
- 阐明了oleuropein aglycone神经保护作用背后的分子机制.
主要方法:
- 使用神经母细胞瘤细胞系和Caenorhabditis elegans模型过度表达α-synuclein.
- 用预制的α-synuclein纤维来评估化合物效应.
- 进行分子建模模拟,以预测化合物-蛋白相互作用.
- 在动物模型中评估了健康期,寿命,运动功能和多巴胺能神经元损失.
主要成果:
- 欧蛋白甘氨酸减少了细胞中早期的α-synuclein总负担.
- 该化合物中和了预制的α-synuclein纤维的毒性.
- 在动物模型中,oleuropein aglycone增强了健康和寿命,改善了运动缺陷,并保留了多巴胺基神经元.
- 分子建模表明与早期的α-synuclein oligomers的相互作用.
结论:
- 欧蛋白甘氨酸显示出针对α-synuclein聚合和毒性的显著神经保护潜力.
- 这些发现支持进一步调查欧蛋白甘作为帕金森病和相关疾病的治疗药物.
- 了解分子相互作用为未来针对α-synuclein病理学的药物开发提供了基础.
更多相关视频
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.7K
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
6.1K
相关概念视频
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Neural Regulation
40.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.1K
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
